Skip to content
DataLookout
Menu

NCT07905352

A Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)
Timeframe: 52 Weeks

Secondary (14)

Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item (ADAS-Cog13)
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
15-item Geriatric Depression Scale (GDS-15)
Mini-Mental State Examination (MMSE)
Plasma p-tau181
Show 9 moreShow less
Plasma p-tau217
Plasma p-tau231
Plasma Aβ42
Plasma Aβ40
Plasma Aβ42/Aβ40 Ratio
Plasma Glial Fibrillary Acidic Protein (GFAP)
Plasma Neurofilament Light Chain (NfL)
Brain Aβ-PET Centiloid (CL)
Adverse Events (AEs) and Serious Adverse Events (SAE

Arms and interventions

Simenafil Hydrochloride TabletsExperimental

2.5 mg/5 mg /10 mg, administered orally once daily for 52consecutive weeks

Placebo TabletPlacebo comparator

Administered orally once daily for 52 consecutive weeks

Drugs: Simenafil Hydrochloride Tablets 2.5 mg, Simenafil Hydrochloride Tablets 5 mg, Simenafil Hydrochloride Tablets 10 mg, Placebo Tablets

Sites

1 site in 1 country

  • Xuanwu Hospital ,Capital Medical UniversityBeijing, Beijing Municipality, China